Eli L. Diamond
Memorial Sloan Kettering Cancer Center
PathologyImmunologyErdheim–Chester diseaseHistiocytosisMedicine
What is this?
Publications 113
#1Gaurav Goyal (UAB: University of Alabama at Birmingham)H-Index: 9
#1Gaurav Goyal (UAB: University of Alabama at Birmingham)H-Index: 1
Last. Kazuhiro Toyama (UTokyo: University of Tokyo)H-Index: 4
view all 25 authors...
Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAP-kinase (RAS-RAF-MEK-ERK) pathway mutations. Typical findings of ECD include central diabetes insipidus, restrictive pericarditis, perinephric fibrosis, and sclerotic bone lesions. The histopathologic diagnosis of ECD is often challenging due to non-specific inflammatory and fibrotic findings on histopathologic review of tissue specimens. A...
5 CitationsSource
#1Jasmine H. Francis (Cornell University)H-Index: 18
#2Eli L. Diamond (Cornell University)H-Index: 22
Last. David H. Abramson (Cornell University)H-Index: 57
view all 6 authors...
Background: Central retinal vein occlusion (CRVO) is a visually threatening event that has rarely been observed in patients taking MEK1/2 inhibitors and that may necessitate permanent discontinuation of a potentially efficacious therapy. We investigated the clinical characteristics of CRVO in patients on mitogen-activated protein kinase kinase (MEK) inhibition to better understand their predisposing factors and clinical course. Case Series: This was a single-center, retrospective cohort study (b...
#1Sonia Mahajan (NYU: New York University)
#1Sonia Mahajan (NYU: New York University)
Last. Heiko SchöderH-Index: 62
view all 9 authors...
BACKGROUND: The role of imaging in the management of Rosai-Dorfman disease (RDD), a rare non-Langerhans cell histiocytosis, is not clearly defined. We present an analysis of FDG PET/CT findings obtained for initial disease characterization, follow-up evaluation, and treatment planning for this disease. METHODS: From an institutional pathology database (2001-2018), we identified RDD patients who underwent FDG PET/CT scans either as part of clinical care or when done as part of clinical trials. Fo...
#1Allison J. Applebaum (Cornell University)H-Index: 1
#1Allison J. Applebaum (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 16
Last. Katherine S. Panageas (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 62
view all 11 authors...
AbstractResearch examining the experience of informal caregivers (ICs) for patients with rare cancers is limited. This was a mixed-methods pilot study of 14 ICs for patients with Erdheim–Chester di...
#1Vivek Subbiah (University of Texas MD Anderson Cancer Center)H-Index: 29
#2Igor Puzanov (Roswell Park Cancer Institute)H-Index: 55
Last. Jason Roszik (University of Texas MD Anderson Cancer Center)H-Index: 25
view all 16 authors...
BRAF V600 mutations occur in a wide range of tumor types and RAF inhibition has become standard in several of these cancers. Despite this progress, BRAF V600 mutations have historically been considered a clear demonstration of tumor lineage context-dependent oncogene addiction, based predominantly on the insensitivity of RAF inhibition in colorectal cancer. However, the true broader activity of RAF inhibition pan-cancer remains incompletely understood. To address this, we conducted a multi-cohor...
2 CitationsSource
#1Ankush Bhatia (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 3
#2Vaios Hatzoglou (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 13
Last. Eli L. Diamond (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 22
view all 15 authors...
BACKGROUND: Erdheim-Chester disease (ECD) is a rare histiocytic neoplasm characterized by recurrent alterations in the mitogen-activating protein kinase (MAPK) pathway. The existing literature about the neuro-oncological spectrum of ECD is limited. METHODS: We present retrospective clinical, radiographic, pathologic, molecular, and treatment data from 30 patients with ECD neurohistiocytic involvement treated at a tertiary center. RESULTS: Median age was 52 (range: 7-77) years and 20 (67%) patien...
2 CitationsSource
#1Roei D Mazor (Assuta Medical Center)H-Index: 1
#2Ran Weissman (Ariel University)
Last. Ofer Shpilberg (RMIT: RMIT University)H-Index: 2
view all 10 authors...
Background Erdheim-Chester disease (ECD), a rare inflammatory myeloid neoplasm, is known to be fundamentally reliant on the constitutive activation of the MAPK signaling pathway in the majority of patients. Consequently, inhibition of the V600E-mutant BRAF kinase has proven to be a safe and efficacious long-term therapeutic strategy for BRAF-mutant ECD patients. Nevertheless, in a subset of patients with CNS disease, the efficacy of long-term treatment may diminish, facilitating suboptimal respo...
#1J. RazanamaheryH-Index: 1
Last. Julien HarocheH-Index: 51
view all 16 authors...
Rosai-Dorfman disease (RDD) is a rare histiocytosis characterized by infiltration of tissue by CD68+ S100+CD1a− histiocytes with large nuclei and abundant lesions of emperipolesis.[1][1] The first clinical observations of RDD were of cervical lymphadenopathy,[2][2] but later extranodal locations[3
10 CitationsSource
#1Carl E. Allen (BCM: Baylor College of Medicine)H-Index: 31
#2Peter Beverley (NIH: National Institutes of Health)H-Index: 4
Last. Astrid G. S. van Halteren (LUMC: Leiden University Medical Center)H-Index: 18
view all 10 authors...
Progress in understanding the rare disease Langerhans cell histiocytosis has stimulated immersive meetings occurring annually over a 30-year period that bring together clinicians, scientists and patients in a unique collaboration.
#1Benjamin H. Durham (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 20
#2Estibaliz Lopez Rodrigo (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
Last. Omar Abdel-Wahab (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 72
view all 36 authors...
Histiocytoses are clonal hematopoietic disorders frequently driven by mutations mapping to the BRAF and MEK1 and MEK2 kinases. Currently, however, the developmental origins of histiocytoses in patients are not well understood, and clinically meaningful therapeutic targets outside of BRAF and MEK are undefined. In this study, we uncovered activating mutations in CSF1R and rearrangements in RET and ALK that conferred dramatic responses to selective inhibition of RET (selpercatinib) and crizotinib,...
9 CitationsSource